Department of Neuropathology, School of Medicine, University of Tokyo, Tokyo, Japan.
Alzheimers Dement. 2010 May;6(3):297-9. doi: 10.1016/j.jalz.2010.03.011.
Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) was launched in 2008, aiming at conducting a longitudinal workup of a standardized neuroimaging, biomarker and clinico-psychological surveys. The research protocol was designed to maximize compatibility with that of US-ADNI, including structural magnetic resonance imaging analysis for the evaluation of brain atrophy, fluorodeoxyglucose and amyloid positron emission tomography, cerebrospinal fluid sampling, APOE genotyping, together with a set of clinical and psychometric tests that were prepared to achieve the highest compatibility to those used in the United States. Japanese ADNI has recruited approximately 357 participants (142 amnestic mild cognitive impairment, approximately 134 normal aged and 72 mild Alzheimer's disease (AD), as of April 15, 2010). World-wide ADNI activities will establish the rigorous quantitative descriptions of the natural course of AD in its very early stages. The data, as well as the methodologies and infrastructures, will facilitate the clinical trials of disease-modifying therapies for AD using surrogate biomarkers.
日本阿尔茨海默病神经影像学倡议 (J-ADNI) 于 2008 年启动，旨在对标准化神经影像学、生物标志物和临床心理学调查进行纵向研究。该研究方案旨在与美国 ADNI 最大程度地兼容，包括用于评估脑萎缩的结构磁共振成像分析、氟代脱氧葡萄糖和淀粉样蛋白正电子发射断层扫描、脑脊液采样、APOE 基因分型，以及一套临床和心理计量测试，这些测试旨在与美国使用的测试达到最高的兼容性。截至 2010 年 4 月 15 日，日本 ADNI 已招募了约 357 名参与者（142 名遗忘型轻度认知障碍，约 134 名正常年龄和 72 名轻度阿尔茨海默病 (AD)）。全球 ADNI 活动将对 AD 早期的自然病程进行严格的定量描述。这些数据以及方法和基础设施将有助于使用替代生物标志物进行 AD 疾病修饰治疗的临床试验。
